Norio Yasui

1.2k citations

37 papers · 963 indexed · h-index 19

Co-authors: Sunao Kaneko Koichi Otani Tadashi Ohkubo Kazunobu Sugawara John A. Katzenellenbogen Kazuo Mihara Tsuyoshi Kondo Akihito Suzuki
Topics: Schizophrenia research and treatment (17 papers)Bipolar Disorder and Treatment (9 papers)Epilepsy research and treatment (9 papers)
Cited by: Pharmacology Psychiatry and Mental health Developmental Neuroscience
Journals: Proceedings of the National Academy of Sciences PLoS ONE Scientific Reports
Partner nations: Japan United States Sweden

In The Last Decade

Norio Yasui

35 papers receiving 940 citations

Peers

Countries citing papers authored by Norio Yasui

Since Specialization

Citations

This map shows the geographic impact of Norio Yasui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norio Yasui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norio Yasui more than expected).

Fields of papers citing papers by Norio Yasui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norio Yasui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norio Yasui. The network helps show where Norio Yasui may publish in the future.

Co-authorship network of co-authors of Norio Yasui

This figure shows the co-authorship network connecting the top 25 collaborators of Norio Yasui. A scholar is included among the top collaborators of Norio Yasui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norio Yasui. Norio Yasui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. 2025 ·PubMed ·Ümmüşen Kaya Akça,Yujun Zhang,Norio Yasui,Christopher Hensley,Anna G. Sorace,Benjamin M. Larimer,Jonathan McConathy	0
2	Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis 2019 ·Scientific Reports ·(unknown),Sung Hoon Kim,Kelli Lauderdale,Andrew Lapato,(unknown),Norio Yasui,(unknown),(unknown),John A. Katzenellenbogen,Seema K. Tiwari‐Woodruff	18
3	Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo 2013 ·Journal of Materials Chemistry B ·Hang Xing,Li Tang,Xujuan Yang,Kevin Hwang,Wendan Wang,Qian Yin,Ngo Yin Wong,Lawrence W. Dobrucki,Norio Yasui,John A. Katzenellenbogen,William G. Helferich,Jianjun Cheng,Yi Lu	161
4	No relationship between −141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study 2001 ·Psychiatry Research ·Kazuo Mihara,Tsuyoshi Kondo,Akihito Suzuki,Norio Yasui,Shingo Ono,Koichi Otani,Sunao Kaneko	20
5	Effect of a Genetic Polymorphism of CYP1A2 Inducibility on the Steady State Plasma Concentrations of Haloperidol and Reduced Haloperidol in Japanese Patients With Schizophrenia 2000 ·Therapeutic Drug Monitoring ·Kazuo Mihara,Akihito Suzuki,Tsuyoshi Kondo,Norio Yasui,Hanako Furukori,(unknown),Shingo Ono,Sunao Kaneko,Koichi Otani,Yoshimasa Inoue	13
6	Prolactin response to nemonapride, a selective antagonist for D 2 like dopamine receptors, in schizophrenic patients in relation to Taq 1A polymorphism of DRD2 gene 2000 ·Psychopharmacology ·Kazuo Mihara,Tsuyoshi Kondo,Akihito Suzuki,Norio Yasui,(unknown),Shingo Ono,Koichi Otani,Sunao Kaneko	38
7	Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients 1999 ·Psychopharmacology ·Hanako Furukori,Tsuyoshi Kondo,Norio Yasui,Koichi Otani,(unknown),(unknown),Sunao Kaneko,Yoshimasa Inoue	11
8	Characteristics and Risk Factors of Acute Dystonia in Schizophrenic Patients Treated With Nemonapride, a Selective Dopamine Antagonist 1999 ·Journal of Clinical Psychopharmacology ·(unknown),Koichi Otani,(unknown),Masayuki Ishida,Norio Yasui,Sunao Kaneko	7
9	Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia 1999 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown),Tadashi Ohkubo,Kazunobu Sugawara,Norio Yasui,Hanako Furukori,Sunao Kaneko	39
10	Effects of Carbamazepine Coadministration on Plasma Concentrations of the Enantiomers of Mianserin and of its Metabolites 1999 ·Therapeutic Drug Monitoring ·Chin B. Eap,Norio Yasui,Sunao Kaneko,Pierre Baumann,Kerry Powell,(unknown)	12
11	Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol 1998 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Norio Yasui,(unknown),Tsuyoshi Kondo,(unknown),Hanako Furukori,Sunao Kaneko,Yoshimasa Inoue	3
12	Prolactin Response to Bromperidol Treatment in Schizophrenic Patients 1998 ·Pharmacology & Toxicology ·Norio Yasui,Tsuyoshi Kondo,Koichi Otani,Masayuki Ishida,Kazuo Mihara,Akihito Suzuki,Sunao Kaneko,Yoshimasa Inoue	18
13	Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam 1998 ·Psychopharmacology ·Norio Yasui,Tsuyoshi Kondo,Koichi Otani,Hanako Furukori,Sunao Kaneko,Tadashi Ohkubo,(unknown),Kazunobu Sugawara	51
14	Single-Dose Pharmacokinetics and Pharmacodynamics of Oral Triazolam in Relation to Cytochrome P4502C19 (CYP2C19) Activity 1997 ·Therapeutic Drug Monitoring ·Norio Yasui,Koichi Otani,Tadashi Ohkubo,Takako Osanai,Kazunobu Sugawara,Kan Chiba,Takashi Ishizaki,Sunao Kaneko	7
15	Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients 1997 ·Pharmacogenetics ·Norio Yasui,Gunnel Tybring,Koichi Otani,Kazuo Mihara,(unknown),Jan‐Olof Svensson,Sunao Kaneko	20
16	Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients 1997 ·Pharmacogenetics ·Akihito Suzuki,Koichi Otani,Kazuo Mihara,Norio Yasui,Sunao Kaneko,Yoshimasa Inoue,Kunihiko Hayashi	57
17	Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m -chlorophenylpiperazine 1997 ·Psychopharmacology ·Kazuo Mihara,K. Otani,Akihito Suzuki,Norio Yasui,Hajime Nakano,Xianmin Meng,Tadashi Ohkubo,(unknown),Sunao Kaneko,Shigeki Tsuchida,Kazunobu Sugawara,Frank J. Gonzalez	30
18	No Effect of the Anticholinergic Drugs Trihexyphenidyl and Biperiden on the Plasma Concentrations of Bromperidol and Its Reduced Metabolite 1997 ·Therapeutic Drug Monitoring ·Koichi Otani,Masayuki Ishida,Norio Yasui,Tsuyoshi Kondo,Kazuo Mihara,Akihito Suzuki,Sunao Kaneko,Yoshimasa Inoue,Masahiro Shibata,(unknown)	10
19	Increases in Plasma Concentration of m-Chlorophenylpiperazine, but not Trazodone, with Low-Dose Haloperidol 1997 ·Therapeutic Drug Monitoring ·Kazuo Mihara,Koichi Otani,Masayuki Ishida,Norio Yasui,Akihito Suzuki,Tadashi Ohkubo,Takako Osanai,Sunao Kaneko,Kazunobu Sugawara	11
20	No interaction between desipramine and bromperidol 1996 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·(unknown),(unknown),Masayuki Ishida,Norio Yasui,Tsuyoshi Kondo,Kazuo Mihara,Sunao Kaneko,(unknown)	2

About Norio Yasui

Norio Yasui is a scholar working on Psychiatry and Mental health, Biological Psychiatry and Pharmacology, having authored 37 papers that have together received 963 indexed citations. Recurring topics across this work include Schizophrenia research and treatment (17 papers), Bipolar Disorder and Treatment (9 papers) and Epilepsy research and treatment (9 papers). The work is most often cited by research in Pharmacology (263 citations), Psychiatry and Mental health (223 citations) and Developmental Neuroscience (43 citations). Norio Yasui has collaborated with scholars based in Japan, United States and Sweden. Frequent co-authors include Sunao Kaneko, Koichi Otani, Tadashi Ohkubo, Kazunobu Sugawara, John A. Katzenellenbogen, Kazuo Mihara, Tsuyoshi Kondo, Akihito Suzuki, Hanako Furukori and Takako Osanai. Their work appears in journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact